Sign InBreakout Stocks of Week 9 @ OMX
NASDAQ was up last week (week 8) by 1.51% ending at 22,886.07 points after gaining 339.40 points during the week. Our system has detected some possible breakout stocks for the following week and these should be on your watchlist. These are the stocks that are bouncing up with good increase in volume and are likely to do good in short term. One of these stocks are Eastnine AB (publ) OMX:EAST. This stock has had a buy signal since Feb 20, 2026 when the price was kr47.25 , but have so far fallen 0% to kr47.25. Some other companies are on our watchlist to, among these are AQ Group AB OMX:AQ Xvivo Perfusion AB (publ) OMX:XVIVO Duni AB OMX:DUNI and Camurus AB (publ) OMX:CAMX which all got a breakout pattern emerging.
| Date | Company | Price | Week 9 |
|---|---|---|---|
| Eastnine Ab (publ) | kr47.25 | kr47.40 | 0.317% |
| Aq Group Ab | kr184.30 | kr189.70 | 2.93% |
| Xvivo Perfusion Ab (publ) | kr189.10 | kr187.50 | -0.85% |
| Duni Ab | kr97.00 | kr97.90 | 0.93% |
| Camurus Ab (publ) | kr532.50 | kr503.00 | -5.54% |
The Eastnine AB (publ) stock price gained 1.50% on the last trading day (Friday, 20th Feb 2026), rising from kr46.55 to kr47.25. During the last trading day the stock fluctuated 1.93% from a day low at kr46.70 to a day high of kr47.60. The price has been going up and down for this period, and there has been a -3.67% loss for the last 2 weeks. Volume fell on the last day by -796 thousand shares and in total, 279 thousand shares were bought and sold for approximately kr13.20 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
Eastnine AB (publ) holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About Eastnine AB (publ):
Eastnine AB (publ) is a real estate investment firm. The firm seeks to make emerging growth investments. In the beginning of 2017 it shifted its focus from both public and unlisted equity investments to purely real estate, where it makes investments in direct and fund of fund stages. It may also invest in special situations on a selective basis. The firm invests in real estate sectors only. For real estate sector, it can also invest in land, real property, and other real estate assets. It primarily invests in Eastern Europe, Russia and other CIS countries including Ukraine, Kazakhstan, Belarus, Uzbekistan, Turkmenistan, Azerbaijan, Georgia, Armenia, Kyrgyzstan, Tajikistan, and Moldova; the Balkans; the Baltic States; and Central Europe. The firm can also make investments into future East Capital private equity funds and real estate funds as well as in existing and future East Capital alternative funds. It also has the possibility to make limited investments in East Capital's open-ended daily-traded funds. The firm is a long term active investor. The firm makes balance sheet investments. Eastnine AB (publ), formerly know as East Capital Explorer AB. was founded in November 2007 and is based in Stockholm, Sweden with additional office in Tallinn, Estonia, Vilnius, Lithuania, Riga, Latvia.
The AQ Group AB stock price gained 1.38% on the last trading day (Friday, 20th Feb 2026), rising from kr181.80 to kr184.30. It has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 2.99% from a day low at kr180.50 to a day high of kr185.90. The price has fallen in 5 of the last 10 days and is down by -7.39% for this period. Volume fell on the last day by -98 thousand shares and in total, 50 thousand shares were bought and sold for approximately kr9.20 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
AQ Group AB holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
The Xvivo Perfusion AB (publ) stock price gained 2.00% on the last trading day (Friday, 20th Feb 2026), rising from kr185.40 to kr189.10. During the last trading day the stock fluctuated 4.29% from a day low at kr181.80 to a day high of kr189.60. The price has been going up and down for this period, and there has been a -5.92% loss for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 7 thousand more shares were traded than the day before. In total, 111 thousand shares were bought and sold for approximately kr21.06 million.
Xvivo Perfusion AB (publ) holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About Xvivo Perfusion AB (publ):
Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.
The Duni AB stock price fell by -0.615% on the last day (Friday, 20th Feb 2026) from kr97.60 to kr97.00. During the last trading day the stock fluctuated 1.77% from a day low at kr96.00 to a day high of kr97.70. The price has fallen in 6 of the last 10 days and is down by -4.15% for this period. Volume has increased on the last day by 99 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 116 thousand shares were bought and sold for approximately kr11.21 million.
Duni AB holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
The Camurus AB (publ) stock price gained 3.40% on the last trading day (Friday, 20th Feb 2026), rising from kr515.00 to kr532.50. During the last trading day the stock fluctuated 4.47% from a day low at kr515.00 to a day high of kr538.00. The price has fallen in 6 of the last 10 days and is down by -22.43% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 100 thousand more shares were traded than the day before. In total, 198 thousand shares were bought and sold for approximately kr105.37 million.
Camurus AB (publ) holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
About Camurus AB (publ):
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Despite these candidates are looking good from a technical perspective they may not perform as expected. You should always be cautious when trading and base your decisions on more than one source of information. This does not constitute an offer or recommendation to buy or sell securities.
GOLDEN STAR
| Ticker | Change | Signal Date |
|---|---|---|
TPR
$140.47
|
0.306% | Jun 04 |
|
N
NVRI
$19.53
|
1.79% | May 20 |
RUN
$12.83
|
4.91% | May 06 |
GLBE
$31.61
|
1.71% | May 05 |
SAP
$172.39
|
5.53% | May 05 |
